OTCMDVHGF
Market cap16mUSD
Dec 18, Last price
0.13USD
Name
Devonian Health Group Inc
Chart & Performance
P/E
—
P/S
1.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.58%
Rev. gr., 5y
24.58%
Revenues
18m
+659.60%
Net income
-1m
L-73.38%
CFO
6m
P
Earnings
Mar 25, 2025
Profile
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | 2016‑07 | 2015‑06 | |
| Income | ||||||||||
Revenues | 17,816 659.60% | 2,345 1.74% | 2,305 56.32% | |||||||
Cost of revenue | 18,674 | 6,745 | 5,335 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (858) | (4,399) | (3,030) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 937 | |||||||||
Tax Rate | ||||||||||
NOPAT | (858) | (4,399) | (3,967) | |||||||
Net income | (1,225) -73.38% | (4,600) 33.39% | (3,448) 3.05% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 708 | 1,163 | 10,763 | |||||||
BB yield | -20.09% | |||||||||
| Debt | ||||||||||
Debt current | 2,120 | 3,602 | 6 | |||||||
Long-term debt | 296 | 167 | 4,294 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (7,446) | (1,294) | (3,505) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | 5,634 | (4,356) | (2,872) | |||||||
CAPEX | (4) | (79) | ||||||||
Cash from investing activities | (4) | 5,000 | (5,079) | |||||||
Cash from financing activities | (830) | 1,614 | 10,411 | |||||||
FCF | (644) | (4,225) | (4,930) | |||||||
| Balance | ||||||||||
Cash | 9,863 | 5,063 | 7,805 | |||||||
Long term investments | ||||||||||
Excess cash | 8,972 | 4,946 | 7,690 | |||||||
Stockholders' equity | 3,187 | 10,483 | 12,596 | |||||||
Invested Capital | 13,521 | 12,976 | 12,861 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 135,566 | 119,028 | ||||||||
Price | 0.19 | 0.45 -6.25% | ||||||||
Market cap | 53,563 25.60% | |||||||||
EV | 50,058 | |||||||||
EBITDA | (186) | (3,976) | (2,166) | |||||||
EV/EBITDA | ||||||||||
Interest | 380 | 460 | 937 | |||||||
Interest/NOPBT | ||||||||||